资讯

Targeted Oncology21 小时
Myeloma Research Sees Transformation Following ODAC Support For MRD End Point
In an interview with Targeted Oncology, C. Ola Langren, MD, discussed the continuing impact of the groundbreaking FDA ODAC ...
European Medical Journal1 天
Minimal Residual Disease: Predicting and Preventing Relapse in Myeloma
In the evolving landscape of haematologic cancers, the concept of minimal residual disease, also known as measurable residual ...
Targeted Oncology1 天
One Year After ODAC Decision: Myeloma Studies Move to Adopt MRD End Point
In the last year, there has been excitement about the use of MRD in multiple myeloma trials and new approaches to assessing ...